Cure8 research brief
The study identifies how secreted products from Lactobacillus brevis can selectively lower inflammatory gene expression in an intestinal epithelial cell model, pointing to microbiome-derived mechanisms that might become targets for future IBD research or therapies.
Researchers (microbiome, immune signaling), clinicians following translational microbiome research, and patients interested in the science behind probiotics/postbiotics.
This lab study tested how metabolites secreted by Lactobacillus brevis (cell-free supernatant, CFS) change gene expression in a human intestinal epithelial cell model (HT-29) exposed to dextran sulfate sodium (DSS) to simulate inflammatory stress. The researchers measured mRNA for 84 Toll-like receptor (TLR) and innate-immune pathway genes using a PCR array.
L. brevis CFS reduced expression of multiple inflammation-associated genes (for example TLR2, TLR4, MYD88, NFKB1, IL1A/B, IL6, PTGS2) while producing a mixed effect on host-defense genes: several TRIF-dependent antiviral genes were downregulated (TLR3, TICAM1, IRF3, CXCL10) whereas other TLR-related genes (TLR1, TLR10, TICAM2, BTK) were upregulated.
The authors interpret this as selective modulation of TLR-related transcription rather than blanket suppression. This report is an in vitro mechanistic study of bacterial metabolites acting on epithelial cells; it does not test a probiotic product, safety, or clinical outcomes in people with IBD.
It suggests specific pathways that could be studied further in animal models or human trials.
Findings come from a controlled cell-culture experiment (HT-29 cells plus DSS) and report transcriptional changes only. They do not provide evidence about clinical benefit, probiotic strains or dosing, or safety in people with IBD.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing interests: The authors declare no competing interests. Conflict of interest: Authors declare no conflict of interest. CRediT authorship contribution statement: Alireza Moghanlou (Moghanlou@yahoo.com): Data curation. Shima Rasouli (shrs84@iau.ac.ir): Writing – original draft. Sheyda Asadi Lanjavani (asadish@gmail.com): Investigation. Sarvenaz Falsafi (dr.sfalsafi@gmail.com): Investigation. Behrouzi Ava (avabehrouzi696463@iau.ac.ir): Writing – original draft.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests dietary tryptophan might reduce bacterial-induced acute lung injury in the context of colitis by altering gut–lung immune signaling, which could be relevant to IBD patients who are at risk for...
People with IBD might be interested because the study explores a new natural-product intervention that appears to reduce colitis severity in an animal model by activating the Nrf2 antioxidant pathway — a pathway already...
The study suggests a novel plant-derived nanoparticle approach reduced inflammation and repaired barrier function in a mouse model of colitis and changed the gut microbiome — a potential early-stage route for new IBD...
